Literature DB >> 3381856

Vaginal reconstruction after exenteration with use of gracilis myocutaneous flaps: the University of California, San Francisco experience.

C G Lacey1, J L Stern, S Feigenbaum, E C Hill, C A Braga.   

Abstract

At the University of California, San Francisco Medical Center we have performed 18 vaginal reconstructive procedures with gracilis flaps at the time of anterior, posterior, or total pelvic exenteration. We have compared these patients with 13 other patients undergoing exenteration during the same interval who chose not to have vaginal reconstruction. There was no significant difference between the two groups with respect to age, weight, operating time, blood loss, or duration of postoperative hospitalization, but there were significantly fewer serious complications in the patients receiving gracilis flaps. The results of a questionnaire indicated that the perineal cosmetic results are highly acceptable, although residual scarring on the legs is a common source of minor complaint. Sexual adjustment can be complete or nearly complete in surviving patients. Given the major contribution to wound healing, reduced postoperative morbidity, excellent cosmetic results, and the opportunity for complete sexual rehabilitation, we believe the gracilis myocutaneous flap neovagina remains the procedure of choice for most women undergoing major exenterative procedures.

Entities:  

Mesh:

Year:  1988        PMID: 3381856     DOI: 10.1016/0002-9378(88)90357-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Reconstruction of an Irradiated Perineal Wound With a Superior Gluteal Artery Perforator Flap.

Authors:  Yangshu L Pan; Albert H Chao
Journal:  Eplasty       Date:  2017-11-30

2.  Simple neovaginoplasty using spontaneous regeneration ability of labial and vestibular flap in patients with Müllerian agenesis.

Authors:  Hwa Sook Moon; Jaseong Koo; Hyeyoung Lee; Bo Sun Joo
Journal:  Gynecol Minim Invasive Ther       Date:  2017-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.